Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-288 Low Dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABT-288 Dose 1 | EXPERIMENTAL | low dose of ABT-288 |
| ABT-288 Dose 2 | EXPERIMENTAL | high dose of ABT-288 |
| Sugar Pill | PLACEBO_COMPARATOR | inactive substance |
| Name | Type | Description |
|---|---|---|
| ABT-288 Low Dose | DRUG | - |
| Placebo | DRUG | inactive substance |
| ABT-288 High Dose | DRUG | - |
Inclusion Criteria: * Has current DSM-IV-TR diagnosis of schizophrenia confirmed by the Mini-International Neuropsychiatric Interview. * Is clinically stable while receiving antipsychotic therapy with one or two atypical antipsychotic medications: lack of hospitalizations from 4 months of Initial S...
ABT-288 Low Dose is an investigational small molecule being developed for the treatment of cognitive deficits in schizophrenia. It is intended to address cognitive symptoms associated with the psychiatric condition, which are distinct from the positive symptoms like hallucinations or delusions.
ABT-288 Low Dose is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with cognitive deficits in schizophrenia.
ABT-288 Low Dose is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind, placebo-controlled study. The drug is still investigational and has not been approved by regulatory authorities for commercial use.
ABT-288 Low Dose has been studied in one clinical trial, identified as NCT01077700. This Phase 2 study, titled 'Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia,' was completed and enrolled 214 participants in the United States. The trial was randomized, double-blind, and placebo-controlled.
ABT-288 Low Dose is not FDA approved. It is an investigational drug currently in Phase 2 clinical development. The completed Phase 2 trial was designed to evaluate its efficacy and safety for cognitive deficits in schizophrenia, but the drug has not yet received regulatory approval.